GoAI
Get started
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

TRVI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$17.96

−$0.29 · -1.59%

Aug 21, 4:00 PM ET

TRVI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

71

Gaining

Sentiment

57

Mixed

Risk resilience

55

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jennifer L. Good
Listed since
May 7, 2019
Employees
34

Market position

Day range

Current $17.96

52-week range

Current $17.96

Open
$18.24
Previous close
$18.25
Volume
1.14M
0.57× average
Average volume
1.99M
Average daily volume
Market cap
2.55B USD
Beta
1.07
Market reference 1
50-day average
$17.7416
+1.23% above average
200-day average
$13.7295
+30.81% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.8B USD
P/E (TTM)
-53.17×
P/B (TTM)
8.75×
P/S (TTM)
0×
EV / EBITDA
-42.14×
Earnings yield
-2.35%
Free cash flow yield
-2.32%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-23.33%
Return on assets
-22.10%
Return on invested capital
-26.77%

Financial health

Debt / equity
0×
Current ratio
19.66×

Financial statements

Income trends

Operating income

−49.33M USD+4.26%

Net income

−42.76M USD+10.75%
Income trends across reported periods−26.82M USD−35.8M USD−44.79M USD−53.77M USDOperating income, FY2021: −32.48M USDOperating income, FY2022: −29.91M USDOperating income, FY2023: −33.92M USDOperating income, FY2024: −51.52M USDOperating income, FY2025: −49.33M USDNet income, FY2021: −33.94M USDNet income, FY2022: −29.15M USDNet income, FY2023: −29.07M USDNet income, FY2024: −47.91M USDNet income, FY2025: −42.76M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −32.48M USD. Operating income FY2022 −29.91M USD. Operating income FY2023 −33.92M USD. Operating income FY2024 −51.52M USD. Operating income FY2025 −49.33M USD. Net income FY2021 −33.94M USD. Net income FY2022 −29.15M USD. Net income FY2023 −29.07M USD. Net income FY2024 −47.91M USD. Net income FY2025 −42.76M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development33.48M USD39.38M USD23.68M USD19.83M USD22.98M USD
Selling, general, and administrative15.85M USD12.15M USD10.24M USD10.07M USD9.49M USD
Operating expenses49.33M USD51.52M USD33.92M USD29.91M USD32.48M USD
Interest income6.54M USD3.6M USD4.75M USD1.74M USD10K USD
Interest expense—4K USD391K USD780K USD1.2M USD
Depreciation and amortization144K USD147K USD123K USD43K USD50K USD
Operating income−49.33M USD−51.52M USD−33.92M USD−29.91M USD−32.48M USD
Net income−42.76M USD−47.91M USD−29.07M USD−29.15M USD−33.94M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+5.49%
11 comparable reports
Latest EPS result
-0.11
Estimate -0.11 · Miss by 0.49%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-0.09-0.13-0.17Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual -0.11, estimate -0.12, surprise +8.33%, Beat. Q2 2025, reported May 8, 2025: actual -0.09, estimate -0.13, surprise +30.77%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.09, estimate -0.1, surprise +10.00%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.08, estimate -0.1, surprise +20.00%, Beat. Q1 2026, reported Mar 17, 2026: actual -0.06, estimate -0.1, surprise +40.00%, Beat. Q2 2026, reported May 5, 2026: actual -0.09, estimate -0.07, surprise -28.57%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.11, estimate -0.109, surprise -0.49%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.13, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$29.67

65.20% upside
Past 12 months12-month forecastHigh $40.00Average $29.67Low $23.00

TRVI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TRVI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
74.21M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
49.68M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
24.73M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
18.05M
Weight
0.12%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
12.64M
Weight
0.12%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
10.98M
Weight
0.06%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
10.87M
Weight
1.94%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
10.35M
Weight
0.04%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research TRVI

research.disclaimer